ArticleBritish journal of clinical pharmacology2025
Management of hypotension in dihydropyridine calcium channel blocker overdose: The role of high-dose insulin therapy.
Article in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Toxidromes.Nature reviews. Disease primers · 2026Review
- Spotlight commentary-Insulin therapy: Future directions.British journal of clinical pharmacology · 2026Article
- Management of hypotension in dihydropyridine calcium channel blocker overdose: The role of high-dose insulin therapy.British journal of clinical pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAmlodipine poisoning is a leading cause of cardiovascular medication-related deaths, commonly managed with high-dose insulin (HDI) therapy. However, HDI is a vasodilator that is counterproductive in managing vasoplegia. We aim to study HDI therapy in patients with hypotension following dihydropyridine calcium channel antagonist (CCA) overdose.
methodsThis retrospective study includes adult patients (≥15 years) with deliberate dihydropyridine CCA overdose and hypotension (mean arterial pressure <65 mmHg or systolic blood pressure <90 mmHg) managed by two Poisons Information Centres and three toxicology units in Australia (2020-2023). Patients who received HDI were compared with those who did not receive HDI therapy.
resultsThere were 50 patients (31 female [62%], median age 57 years). Forty-one (82%) coingested a renin-angiotensin system antagonist. Ten (20%) received HDI (median bolus dose of 1 U/kg and infusion 1.25 U/kg/h, interquartile range: 0.9-5.5) and 40 (80%) did not receive HDI therapy. Eight patients in the HDI had echocardiogram, 4 showed left ventricular dysfunction. There were no differences in the 2 groups regarding age, sex, median dose of dihydropyridine and renin-angiotensin system antagonists. Median minimal systolic blood pressure (P = .0007) and mean arterial pressure (P = .0006) were significantly lower prior to starting HDI. There were increased maximal concomitant number of vasopressors/inotropes used (median difference: 1.5; P = .0002) and at higher doses in the HDI group. Median dose of noradrenaline used was 1.15 μg/kg/min in the HDI group vs. 0.27 μg/kg/min in the non-HDI group (P = .003). One fatality occurred in the non-HDI group.
conclusionDihydropyridine CCA poisoning with associated hypotension was treated primarily with vasopressor therapy. The inodilator HDI was not commonly used, and it was primarily administered in low doses, utilized mainly in patients with left ventricular dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.